Abstract

Limited data indicated radiotherapy might provide survival benefits to patients with distantly metastatic nasopharyngeal carcinoma (mNPC). We used the Surveillance Epidemiology and End Results database to examine the role of radiotherapy in the treatment of mNPC. Patients with mNPC at presentation diagnosed between 1988 and 2012 were enrolled. The outcome of interest included overall survival (OS) and cancer-specific survival (CSS). A total of 679 patients with a median follow-up of 13 months were identified. Four hundred forty-eight patients received radiotherapy and 231 did not. Radiotherapy was associated with significantly improved OS and CSS in both univariate and multivariate analyses. Weighted Cox regression by inverse probability of treatment weighting (IPTW) using propensity score (PS) showed a 50% reduced risk of mortality in patients who received radiotherapy with regards to both OS (HR: 0.50, 95% CI: 0.41–0.60, p < 0.001) and CSS (HR: 0.50, 95% CI: 0.40–0.61, p < 0.001), respectively. Further, patients with a younger age (<65 year-old), diagnosed after 2003, with non-keratinizing carcinoma or undifferentiated carcinoma, and who received surgery had better outcomes for both OS and CSS. Local radiotherapy was associated with improved survival in patients with mNPC. Our findings warrant prospective investigation in clinical trials.

Highlights

  • The addition of local therapy such as radiation to systemic chemotherapy for metastatic cancer has been practiced for a number of diseases with success in improving treatment outcome including survival

  • While other characteristics were similar in groups with and without radiotherapy

  • 10% of patients are diagnosed with distant metastasis (i.e., Stage IVC)

Read more

Summary

Introduction

The addition of local therapy such as radiation to systemic chemotherapy for metastatic cancer has been practiced for a number of diseases with success in improving treatment outcome including survival. Despite data demonstrating improved survival with tumor burden reduction using radiotherapy in metastatic foci[4, 5] and primary tumor[6,7,8] in other malignancies, the recommended utilization of active radiotherapy or chemoradiation for mNPC patients by NCCN is not supported by any large-scale observational or prospective studies. We conducted a study using the Surveillance, Epidemiology, and End Results (SEER) database to determine whether NPC patients diagnosed with distant metastasis who received radiation therapy had an improved survival compared with patients who did not

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call